Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
Start Today
// //
Subscribe from $1.99/WK
Register
AdChoices

Resverlogix Corp TSX: RVX-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale
Alerts Watchlist Portfolio

Today's Trading

Day Low 0.57
Day High 0.63
Open:0.63
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Latest
number cruncher
Which of these top 10 Canadian biotech stocks are undervalued?
Subscriber content
inside the market
Short sales on the TSX: What bearish investors are betting against
Subscriber content
inside the market
Friday’s small-cap stocks to watch
Subscriber content
inside the market
Monday’s analyst upgrades and downgrades
Subscriber content
inside the market
Thursday’s small-cap stocks to watch
Subscriber content
inside the market
Short-sellers renew bearish bets on marijuana companies
Subscriber content
Description
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

No rating
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
Study Demonstrates Resverlogix's Apabetalone Treatment Significantly Improves Cognition and Reduces Cognitive Decline Among Patients with Both Cardiovascular Disease and Diabetes Mellitus
- GlobeNewswire - Mon Sep 13, 7:09AM CDT
GlobeNewswire - CMTX
Mon Sep 13, 7:09AM CDT
Positive Findings in Journal of Alzheimer's Disease Suggest BET Inhibitor Apabetalone Holds Promise as a Safe and Effective Therapeutic for Vascular Cognitive Impairment
InvestmentPitch Media Video Discusses Resverlogix and Report of its Apabetalone Drug Meeting Primary Endpoint in Pulmonary Arterial Hypertension Investigator Led Pilot Study - Video Available on Investmentpitch.com
- Newsfile Corp - Thu Sep 9, 2:07AM CDT
Newsfile Corp - CMTX
Thu Sep 9, 2:07AM CDT
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2021) - Resverlogix Corp. (TSX: RVX) (OTC Pink: RVXCF) reported that its Apabetalone drug met its primary endpoint in a pulmonary arterial hypertension or 'PAH' investigator led pilot study. Resverlogix, a world leader in epigenetics, or gene regulation, has been pioneering a technology which has the ability to turn multiple disease genes on or off, without changing the human DNA.
Resverlogix Announces Apabetalone Meets Primary Endpoint in a Pulmonary Arterial Hypertension Pilot Study
- GlobeNewswire - Wed Sep 8, 7:00AM CDT
GlobeNewswire - CMTX
Wed Sep 8, 7:00AM CDT
Apabetalone, a First-in-Class Epigenetic Therapeutic Candidate, Met Key Endpoint of Lowering Pulmonary Vascular Resistance (PVR) and Was Well Tolerated
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 0.52 +9.62% increase
on 09/01/21
Period Open:0.61
Price movement based on the high, low and last over the given period.
0.68 -16.18% decrease
on 09/08/21
 -0.04 (-6.56%) decrease
since 08/24/21
3-Month 0.52 +9.62% increase
on 09/01/21
Period Open:0.88
Price movement based on the high, low and last over the given period.
0.90 -36.67% decrease
on 06/28/21
 -0.31 (-35.23%) decrease
since 06/24/21
52-Week 0.52 +9.62% increase
on 09/01/21
Period Open:1.25
Price movement based on the high, low and last over the given period.
1.52 -62.50% decrease
on 09/28/20
 -0.68 (-54.40%) decrease
since 09/24/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies